Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Yasuo Hamamoto

Showing results (21-30 of 121) with videos related to

Pageof 13
Sort By:
Journal of Patient-Reported Outcomes|May 4, 2019
Patient voice on management of facial dermatological adverse events with targeted therapies: a qualitative studyKaori Yagasaki, Hayato Takahashi, Takeshi Ouchi, et al.
Cancer Chemotherapy and Pharmacology|November 26, 2011
Pharmacokinetic analysis of capecitabine and cisplatin in combination with trastuzumab in Japanese patients with advanced HER2-positive gastric cancerTaroh Satoh, Yasushi Omuro, Yasutsuna Sasaki, et al.
Gan to Kagaku Ryoho. Cancer & Chemotherapy|May 14, 2011
[A case of metastatic colon cancer in which repetition of standard treatment proved effective]Tomohiro Nishi, Yasuo Hamamoto, Etsuko Warita, et al.
Investigational New Drugs|January 20, 2011
Phase I trial of sorafenib in combination with interferon-alpha in Japanese patients with unresectable or metastatic renal cell carcinomaMasashi Niwakawa, Katsuyoshi Hashine, Raizo Yamaguchi, et al.
Gan to Kagaku Ryoho. Cancer & Chemotherapy|December 1, 2016
[Physical Activity in Patients with Gastrointestinal Cancer Undergoing Outpatient Chemotherapy]Megumi Iwakoshi, Tetsuya Tsuji, Hiromasa Takaishi, et al.
International Journal of Clinical Oncology|March 19, 2011
Retrospective analysis of the international standard-dose FOLFIRI (plus bevacizumab) regimen in Japanese patients with unresectable advanced or recurrent colorectal carcinomaTomohiro Nishi, Yasuo Hamamoto, Etsuko Warita, et al.
Gastric Cancer : Official Journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association|May 2, 2002
Five-year survivor with liver metastasis from gastric cancer successfully treated with systemic chemotherapyHiroki Saitoh, Narikazu Boku, Atsushi Ohtsu, et al.
Oncology Letters|April 14, 2016
Fatal hemorrhage in a patient with advanced soft tissue sarcoma following radiation and pazopanib treatment: A case reportKenta Kawasaki, Yasuo Hamamoto, Junichi Fukada, et al.
BMC Cancer|June 14, 2020
Weekly paclitaxel plus ramucirumab versus weekly nab-paclitaxel plus ramucirumab for unresectable advanced or recurrent gastric cancer with peritoneal dissemination refractory to first-line therapy-the P-SELECT trial (WJOG10617G)-a randomised phase II trial by the West Japan Oncology GroupKenro Hirata, Yasuo Hamamoto, Masahiko Ando, et al.
Cancer Chemotherapy and Pharmacology|August 13, 2010
A phase II study of paclitaxel by weekly 1-h infusion for advanced or recurrent esophageal cancer in patients who had previously received platinum-based chemotherapyKen Kato, Makoto Tahara, Shuichi Hironaka, et al.
Pageof 13

Showing results (21-30 of 121) with videos related to

Sort By:
Pageof 13
Journal of Patient-Reported Outcomes|May 4, 2019
Patient voice on management of facial dermatological adverse events with targeted therapies: a qualitative studyKaori Yagasaki, Hayato Takahashi, Takeshi Ouchi, et al.
Cancer Chemotherapy and Pharmacology|November 26, 2011
Pharmacokinetic analysis of capecitabine and cisplatin in combination with trastuzumab in Japanese patients with advanced HER2-positive gastric cancerTaroh Satoh, Yasushi Omuro, Yasutsuna Sasaki, et al.
Gan to Kagaku Ryoho. Cancer & Chemotherapy|May 14, 2011
[A case of metastatic colon cancer in which repetition of standard treatment proved effective]Tomohiro Nishi, Yasuo Hamamoto, Etsuko Warita, et al.
Investigational New Drugs|January 20, 2011
Phase I trial of sorafenib in combination with interferon-alpha in Japanese patients with unresectable or metastatic renal cell carcinomaMasashi Niwakawa, Katsuyoshi Hashine, Raizo Yamaguchi, et al.
Gan to Kagaku Ryoho. Cancer & Chemotherapy|December 1, 2016
[Physical Activity in Patients with Gastrointestinal Cancer Undergoing Outpatient Chemotherapy]Megumi Iwakoshi, Tetsuya Tsuji, Hiromasa Takaishi, et al.
International Journal of Clinical Oncology|March 19, 2011
Retrospective analysis of the international standard-dose FOLFIRI (plus bevacizumab) regimen in Japanese patients with unresectable advanced or recurrent colorectal carcinomaTomohiro Nishi, Yasuo Hamamoto, Etsuko Warita, et al.
Gastric Cancer : Official Journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association|May 2, 2002
Five-year survivor with liver metastasis from gastric cancer successfully treated with systemic chemotherapyHiroki Saitoh, Narikazu Boku, Atsushi Ohtsu, et al.
Oncology Letters|April 14, 2016
Fatal hemorrhage in a patient with advanced soft tissue sarcoma following radiation and pazopanib treatment: A case reportKenta Kawasaki, Yasuo Hamamoto, Junichi Fukada, et al.
BMC Cancer|June 14, 2020
Weekly paclitaxel plus ramucirumab versus weekly nab-paclitaxel plus ramucirumab for unresectable advanced or recurrent gastric cancer with peritoneal dissemination refractory to first-line therapy-the P-SELECT trial (WJOG10617G)-a randomised phase II trial by the West Japan Oncology GroupKenro Hirata, Yasuo Hamamoto, Masahiko Ando, et al.
Cancer Chemotherapy and Pharmacology|August 13, 2010
A phase II study of paclitaxel by weekly 1-h infusion for advanced or recurrent esophageal cancer in patients who had previously received platinum-based chemotherapyKen Kato, Makoto Tahara, Shuichi Hironaka, et al.
Pageof 13